Bugs & Drugs

I found that I was losing the plot about what was when and where! Here’s my quick guide to priority pathogens and pipeline reviews. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • CDC 2019: Newsletter is here, report itself is here.
  • WHO 2017: Newsletter is here, report itself is here.
  • CDC 2013: Report itself is here.
  • ESKAPE list 2008-9: The original papers are here:
    • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
    • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
  • Comparative summary of all 4 priority pathogen lists as a PowerPoint deck is here.
    • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class. 

Pipeline Reviews

  • Reviews by WHO
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of April 2020)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2019.
    • Non-traditional products are separately summarized here.
  • Independent reviews

In Praise of Non-Inferiority

Dear All (semi-wonkish but intended for everybody to read and absorb): There’s been a lot of recent discussion about “lessons learned from COVID-19.” Indeed, there are many valuable points: global cooperation, preparedness, supply chains, and so forth. As an example, I note the 17 Sep 2020 communique from the G20 Health Ministers (link): it was heavily

FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference

Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The

Scroll to Top